Advanced search
Publication Cover
Gynecological Endocrinology Volume 40, 2024 - Issue 1
Submit an article Journal homepage
487
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Nonalcoholic fatty liver disease risk in polycystic ovary syndrome patients

Ana M. Fernández-Alonsoa Department of Obstetrics and Gynecology, Torrecárdenas University Hospital, Almería, SpainORCID Iconhttps://orcid.org/0000-0002-4844-2145View further author information
ORCID Icon,
Peter Chedrauib Escuela de Posgrado en Salud, Universidad Espíritu Santo, Samborondón, EcuadorCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-1556-3979View further author information
ORCID Icon &
Faustino R. Pérez-Lópezc Faculty of Medicine, Aragón Health Research Institute, University of Zaragoza, Zaragoza, SpainORCID Iconhttps://orcid.org/0000-0002-2801-416XView further author information
ORCID Icon
Article: 2359031 | Received 25 Mar 2024, Accepted 17 May 2024, Published online: 30 May 2024

References

  • Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine. 2016;51(2):211–221. doi:10.1007/s12020-015-0640-8.
  • Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64(1):19–22. doi:10.1002/hep.28524.
  • Cholongitas E, Pavlopoulou I, Papatheodoridi M, et al. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol. 2021;34(3):404–414. doi:10.20524/aog.2021.0604.
  • Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, et al. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;5(4):496–501. doi:10.1016/j.cgh.2006.10.010.
  • Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47(3):412–417. doi:10.1016/j.jhep.2007.04.012.
  • Genazzani AD, Battipaglia C, Semprini E, et al. Familial diabetes in obese PCOS predisposes individuals to compensatory hyperinsulinemia and insulin resistance (IR) also for reduced hepatic insulin extraction (HIE). Endocrines. 2022;3(2):296–302. doi:10.3390/endocrines3020024.
  • Genazzani AD, Genazzani AR. Polycystic ovary syndrome as metabolic disease: new insights on insulin resistance. touchREV Endocrinol. 2023;19(1):71–77. doi:10.17925/EE.2023.19.1.71.
  • Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: a review article. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100060. doi:10.1016/j.eurox.2019.100060.
  • Zhu JL, Chen Z, Feng WJ, et al. Sex hormone-binding globulin and polycystic ovary syndrome. Clin Chim Acta. 2019;499:142–148. doi:10.1016/j.cca.2019.09.010.
  • Deswal R, Yadav A, Dang AS. Sex hormone binding globulin - an important biomarker for predicting PCOS risk: a systematic review and meta-analysis. Syst Biol Reprod Med. 2018;64(1):12–24. doi:10.1080/19396368.2017.1410591.
  • Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010;25(1):212–220. doi:10.1093/humrep/dep380.
  • Shengir M, Chen T, Guadagno E, et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: a systematic review and meta-analysis. JGH Open. 2021;5(4):434–445. doi:10.1002/jgh3.12512.
  • Huang G, Coviello A. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 2012;19(6):512–519. doi:10.1097/MED.0b013e32835a000e.
  • Manzano-Nunez R, Santana-Dominguez M, Rivera-Esteban J, et al. Non-Alcoholic fatty liver disease in patients with polycystic ovary syndrome: a systematic review, meta-analysis, and meta-Regression. J Clin Med. 2023;12(3):856. doi:10.3390/jcm12030856.
  • Xu Q, Zhang J, Lu Y, et al. Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome. iScience. 2024;27(2):108783. doi:10.1016/j.isci.2024.108783.
  • Yao K, Zheng H, Peng H. Association between polycystic ovary syndrome and risk of non-alcoholic fatty liver disease: a meta-analysis. Endokrynol Pol. 2023;74(5):520–527. doi:10.5603/ep.93291.
  • Maldonado SS, Cedars MI, Yates KP, et al. AntiMullerian hormone, a marker of ovarian reserve, is protective against presence and severity of NASH in premenopausal women. Clin Gastroenterol Hepatol. 2024;22(2):339–346.e5. doi:10.1016/j.cgh.2023.08.020.
  • Cowan S, Grassi A, Monahan Couch L, et al. Evidence-Based lifestyle guidelines and Self-Management strategies utilized by women with polycystic ovary syndrome. Nutrients. 2023;15(3):589. doi:10.3390/nu15030589.
  • Greaves CJ, Sheppard KE, Abraham C, IMAGE Study Group., et al. Intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011;11(1):119. doi:10.1186/1471-2458-11-119.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.